Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of LADA
2008-007945-29Phase 3Active
- Sponsor
- The Institute of Cancer Research
- Start
- Aug 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of metformin, insulin aspart, human insulin, repaglinide and sitagliptin in latent autoimmune diabetes in adults (LADA) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: C-peptide glucagon test outcomes. Started Aug 2009; status: active.
02
Drugs
metformininsulin asparthuman insulinrepaglinidesitagliptin
03
Conditions
latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on 2008-007945-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007945-29.